- Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
- Mirum Pharmaceuticals’ LIVMARLI (maralixibat oral solution) Receives Positive Reimbursement Recommendation by Canada’s CADTH for Patients with Cholestatic Pruritus in Alagille Syndrome
- Mirum Pharmaceuticals’ LIVMARLI Receives FDA Approval for Treatment of Cholestatic Pruritus in Patients with Progressive Familial Intrahepatic Cholestasis
- Mirum Pharmaceuticals to Participate in Upcoming Investor Conferences
- Hepatology Publishes Six-Year Data Demonstrating Improved Clinical Outcomes in Patients with Alagille Syndrome Treated with Mirum’s LIVMARLI
- Mirum Pharmaceuticals Reports Fourth Quarter and Year-End 2023 Financial Results and Provides Business Update
- Mirum Pharmaceuticals to Announce Fourth Quarter and Year-End 2023 Financial Results and Host Conference Call on February 28, 2024
More ▼
Key statistics
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 23.56 |
---|---|
High | 24.62 |
Low | 23.14 |
Bid | 21.00 |
Offer | 25.73 |
Previous close | 24.49 |
Average volume | 408.42k |
---|---|
Shares outstanding | 47.00m |
Free float | 45.06m |
P/E (TTM) | -- |
Market cap | 1.15bn USD |
EPS (TTM) | -4.08 USD |
Data delayed at least 15 minutes, as of Apr 25 2024 21:00 BST.
More ▼